Sunday 18 October 2026 Export CABA’s income statement to Excel — free account

Cabaletta Bio, Inc.

In the quarter to June 2026, EPS grew 53.4% and free cash flow fell 35.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.41 0.14 −9.03%

Follow CABA

Alert me

Market cap: $262.8M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.30

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	8	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.84%

Capital & Financial Ratios $m

Market Cap 262.79

Revenue —

Net Income (181.32)

Free Cash Flow (153.93)

Net Debt (225.10)

Current Ratio 5.79

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.01

Past 5Y EPS Growth —

This Y EPS Growth 35.13%

Next Y EPS Growth 11.96%

Next Y revenue growth —

Next 5Y EPS Growth 22.07%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 36.71%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	241	164	134	225
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	244	167	139	231

	2023	2024	2025	Q'26
Payables	5	5	7	6
ST’ Debt	—	—	—	—
Other	—	6	21	15
	16	27	50	40

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.45%	2.35%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(43)	(42)	—	—	—
’25	(31)	(30)	(35)	(35)	(131)
’24	(24)	(21)	(20)	(23)	(88)
’23	(13)	(12)	(13)	(16)	(54)
’22	(13)	(12)	(10)	(12)	(46)
’21	(9)	(7)	(8)	(11)	(34)
’20	(5)	(8)	(5)	(9)	(27)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(43)	(42)	—	—	—
’25	(32)	(31)	(35)	(36)	(132)
’24	(25)	(22)	(21)	(23)	(90)
’23	(13)	(12)	(13)	(17)	(54)
’22	(13)	(12)	(11)	(12)	(49)
’21	(9)	(7)	(9)	(11)	(35)
’20	(5)	(8)	(5)	(9)	(27)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.39)	(0.34)	—	—	—
’25	(0.71)	(0.73)	(0.44)	(0.40)	(2.10)
’24	(0.51)	(0.56)	(0.62)	(0.65)	(2.34)
’23	(0.45)	(0.37)	(0.37)	(0.46)	(1.65)
’22	(0.45)	(0.45)	(0.39)	(0.52)	(1.81)
’21	(0.41)	(0.45)	(0.45)	(0.49)	(1.80)
’20	(0.33)	(0.35)	(1.95)	(0.40)	(1.44)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	7.56	5.51	3.05	0.59	5.88	1.76	0.99	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	18.28	19.63	15.38	9.95	23.77	26.35	3.67
People
People	Employees	—	—	20	22	34	54	60	103	164	156
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	0	(12)	(17)	(33)	(46)	(53)	(68)	(116)	(168)
	EBT margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	(12)	(17)	(33)	(46)	(53)	(68)	(116)	(168)
	Depreciation	—	—	—	0	0	1	2	1	4	12
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	(0.01)	(10.86)	(4.07)	(1.44)	(1.80)	(1.81)	(1.65)	(2.34)	(2.10)
	Cash flow	—	0.00	(4.15)	(3.69)	(1.54)	(1.60)	(1.78)	(1.37)	(1.80)	(1.64)
	Capex	—	0.00	0.00	(0.16)	(0.04)	(0.05)	(0.09)	(0.02)	(0.05)	(0.02)
	Free cash flow	—	0.00	(4.15)	(3.85)	(1.57)	(1.65)	(1.88)	(1.38)	(1.84)	(1.66)
	Book value	—	(0.01)	29.56	31.83	6.29	5.52	4.02	6.03	3.11	1.40
	Shares, m	—	24	1	4	17	21	26	39	49	80
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(5)	(16)	(27)	(34)	(46)	(54)	(88)	(131)
	Capex	—	—	—	(1)	(1)	(1)	(2)	(1)	(2)	(1)
	Free cash flow	—	—	(5)	(17)	(27)	(35)	(49)	(54)	(90)	(132)
Balance, $m
Balance, $m	Working capital	—	0	33	137	108	116	99	228	140	89
	Total debt	—	—	44	—	—	—	5	—	—	—
	Net debt	—	0	(33)	(136)	(109)	(122)	(107)	(241)	(164)	(134)
	Shareholders’ equity	—	0	33	138	110	118	105	236	152	112
Returns, %
Returns, %	ROA	—	(1.46)	(71.41)	(25.36)	(26.03)	(38.40)	(43.55)	(36.52)	(52.82)	(95.88)
	ROIC	—	0.00	(1,808.70)	(551.58)	(2,397.46)	0.00	0.00	0.00	0.00	0.00
	ROE	—	4.57	223.09	(34.90)	(26.90)	(40.69)	(47.62)	(39.72)	(59.64)	(126.98)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EYPT EyePoint, Inc.	$270.7M	— (loss-making)	— (loss-making)	−90.49% (below 0%: shrinking)	n/m	+0.41% (above 0%: growing)	100.00%	(19,207.10%)	Compare
PALI Palisade Bio, Inc.	$268.4M	2.2×	— (loss-making)	+19,900.00% (above 0%: growing)	n/m	−318.44% (below 0%: shrinking)	100.00%	(2,339.60%)	Compare
ABEO Abeona Therapeutics Inc.	$265.9M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)	Compare
PRLD Prelude Therapeutics Incorporated	$265.0M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)	Compare
CABA Cabaletta Bio, Inc.	$262.8M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%
XFOR X4 Pharmaceuticals, Inc.	$261.8M	— (loss-making)	— (loss-making)	+346.33% (above 0%: growing)	n/m	+13.76% (above 0%: growing)	81.64%	(186.13%)	Compare
RCKT Rocket Pharmaceuticals, Inc.	$259.1M	— (loss-making)	—	—	n/m	+19.16% (above 0%: growing)	0.00%	0.00%	Compare
VNDA Vanda Pharmaceuticals Inc.	$256.4M	— (loss-making)	— (loss-making)	−3.92% (below 0%: shrinking)	n/m	−101.02% (below 0%: shrinking)	92.95%	(126.28%)	Compare
IKT Inhibikase Therapeutics, Inc.	$255.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−123.23% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$263.4M	—	—	+42.60%	—	+7.09%	87.30%	(156.20%)

All 614 Biotechnology stocks →

Cabaletta Bio, Inc. (CABA) key facts

Cabaletta Bio, Inc. (CABA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CABA traded at $1.41, a market capitalization of $262.8 million.
Return on equity was −127.0% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.